Destiny Pharma PLC Dr Debra Barker Appointed Interim CEO (5811A)
May 25 2023 - 2:00AM
UK Regulatory
TIDMDEST
RNS Number : 5811A
Destiny Pharma PLC
25 May 2023
Board Changes
Dr Debra Barker Appointed Interim CEO
Brighton, United Kingdom - 25th May 2023: Destiny Pharma plc
(AIM: DEST), a clinical stage innovative biotechnology company
focused on the development of novel medicines that can prevent
life-threatening infections, today announces, ahead of the AGM,
that Neil Clark has decided to step down as Chief Executive Officer
to pursue new challenges. Neil will also step down from the board
with immediate effect.
Dr Debra Barker, who is currently a Non-Executive Director, will
become interim CEO until a permanent replacement is appointed. Neil
will continue to support the business for a limited period to
ensure an orderly handover. Dr Barker has a wealth of experience as
a senior executive and Board director in life science companies
including the anti-infectives sector having held key roles at
Novartis and Polyphor, in addition to roles at Roche, GSK and
Polyneuron.
Nick Rodgers, Chairman of Destiny Pharma, said: "Neil's
contribution to the Company over the last six years has been
significant. Having recently led the exclusive collaboration and
co-development agreement for NTCD-M3 with Sebela Pharmaceuticals,
raised finance, achieved the publication of landmark XF-73 Phase 2
data, and positive results from the SPOR-COV research, he has
decided that it is the right time for him to move on to a fresh
challenge. He leaves the business well positioned with a strong
balance sheet and a diversified, late-stage pipeline. On behalf of
the Board, I want to thank Neil for the commitment he has shown in
delivering Destiny's strategy over the last 6 years since he led
the IPO of the business in 2017.
"Debra joined Destiny in 2020 and knows the business well. Her
experience of working in various roles at big pharma will play an
integral part in delivering the next phase of Destiny Pharma's
strategy, as we look to maximise the value of our strong product
pipeline."
Dr Debra Barker, Interim Chief Executive Officer of Destiny
Pharma, said: "The business is well positioned to build on the
progress that has been achieved and there are significant
opportunities that lie ahead for the Company. My primary focus will
be on advancing partnership discussions for XF-73 nasal and I look
forward to leading Destiny until the Board appoints a permanent
successor to drive the business through its next phase of
growth."
For further information, please contact:
Destiny Pharma plc
Dr Debra Barker, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com
Optimum Strategic Communications
Mary Clark / Nick Bastin / Jonathan Edwards / Eleanor Cooper
+44 (0) 203 922 0891
DestinyPharma@optimumcomms.com
finnCap Ltd (Nominated Advisor and Joint Broker)
Geoff Nash / George Dollemore, Corporate Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
+44 (0) 207 220 0500
Shore Capital (Joint Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090
Dr Debra Barker biography
Dr Barker has worked at Novartis, Roche, GSK (then SmithKline
Beecham) and most recently in C-Suite roles at Polyphor and
Polyneuron. Dr Barker is currently Senior Independent Director at
Arix Bioscience, a global venture capital company and holds
additional Non-Executive Director positions at BerGenBio ASA, an
immune-oncology company and CureVac AG a clinical stage
biopharmaceutical company with a proprietary RNA technology
platform. At Novartis Dr Barker held several senior roles including
Head of Development for Anti-Infectives, Immunology and
Transplantation. Dr Barker was also the medical lead for Swiss
based anti-infective specialist Polyphor's highly successful IPO on
the SIX Swiss Exchange.
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology
company focused on the development of novel medicines that can
prevent life-threatening infections. Its pipeline has novel
microbiome-based biotherapeutics and XF drug clinical assets
including NTCD-M3, a Phase 3 ready treatment for the prevention of
C. difficile infection (CDI) recurrence which is the leading cause
of hospital acquired infection in the US and also XF-73 nasal gel,
which has recently completed a positive Phase 2b clinical trial
targeting the prevention of post-surgical staphylococcal hospital
infections including MRSA. It is also co-developing SPOR-COV, a
novel, biotherapeutic product for the prevention of COVID-19 and
other viral respiratory infections and has earlier grant funded XF
research projects.
For further information on the company, please visit
www.destinypharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAFZLLLXELLBBE
(END) Dow Jones Newswires
May 25, 2023 02:00 ET (06:00 GMT)
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From Apr 2024 to May 2024
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From May 2023 to May 2024